Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI115547

All-trans retinoic acid modulates the retinoic acid receptor-alpha in promyelocytic cells.

C Chomienne, N Balitrand, P Ballerini, S Castaigne, H de Thé, and L Degos

Laboratoire de Biologie Cellulaire Hématopoïétique, Hôpital Saint Louis, Paris, France.

Find articles by Chomienne, C. in: JCI | PubMed | Google Scholar

Laboratoire de Biologie Cellulaire Hématopoïétique, Hôpital Saint Louis, Paris, France.

Find articles by Balitrand, N. in: JCI | PubMed | Google Scholar

Laboratoire de Biologie Cellulaire Hématopoïétique, Hôpital Saint Louis, Paris, France.

Find articles by Ballerini, P. in: JCI | PubMed | Google Scholar

Laboratoire de Biologie Cellulaire Hématopoïétique, Hôpital Saint Louis, Paris, France.

Find articles by Castaigne, S. in: JCI | PubMed | Google Scholar

Laboratoire de Biologie Cellulaire Hématopoïétique, Hôpital Saint Louis, Paris, France.

Find articles by de Thé, H. in: JCI | PubMed | Google Scholar

Laboratoire de Biologie Cellulaire Hématopoïétique, Hôpital Saint Louis, Paris, France.

Find articles by Degos, L. in: JCI | PubMed | Google Scholar

Published December 1, 1991 - More info

Published in Volume 88, Issue 6 on December 1, 1991
J Clin Invest. 1991;88(6):2150–2154. https://doi.org/10.1172/JCI115547.
© 1991 The American Society for Clinical Investigation
Published December 1, 1991 - Version history
View PDF
Abstract

We have recently demonstrated that all-trans retinoic acid (RA), the active metabolite of vitamin A, is an efficient alternative to chemotherapy in the treatment of acute promyelocytic leukemia (AML3). We have further shown that, in these AML3 cells, the gene of the retinoic acid receptor-alpha (RAR alpha) is translocated from chromosome 17 to chromosome 15, and fused to a new gene, PLM. This results in the expression of both normal and chimeric RAR alpha transcripts in AML3 cells. The PLM-RAR alpha protein may account for the impairment of differentiation and thus leukemogenesis, but not for the paradoxical efficacy of RA in these cells. In an attempt to elucidate RA's differentiative effect in AML3 patients, the present work examined the in vitro and in vivo modulation of the normal RAR alpha transcripts by all-trans RA in seven cases of AML3. In all samples, Northern blot analysis revealed a low expression of the two normal RAR alpha transcripts compared with other human myeloid leukemic cells. No modulation was observed after 4-8 d of in vivo therapy with all-trans RA 45 mg/m2 per d. In vitro incubation with all-trans RA, however, increased the level of expression of the normal RAR alpha transcripts in AML3 cells but not in other AML leukemic subtypes. This modulation of the two normal RAR alpha transcripts appeared to be an early and primary event of RA's differentiating effect. We therefore suggest that up-regulation of the normal RAR alpha gene expression by pharmacological concentrations of all-trans RA may restore the normal differentiation pathway in these cells.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 2150
page 2150
icon of scanned page 2151
page 2151
icon of scanned page 2152
page 2152
icon of scanned page 2153
page 2153
icon of scanned page 2154
page 2154
Version history
  • Version 1 (December 1, 1991): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts